Scarica l'app Stockscreener
25.45
1.03%
0.26
Pre-mercato:
25.45
Alto Neuroscience Inc Borsa (ANRO) Ultime notizie
Alto Neuroscience (ANRO) Price Target Increased by 81.11% to 19.09 - MSN
BofA Securities Initiates Alto Neuroscience(ANRO.US) With Buy Rating, Announces Target Price $35 - Moomoo
BofA initiates Alto Neuroscience stock coverage with buy rating By Investing.com - Investing.com India
BofA initiates Alto Neuroscience stock coverage with buy rating - Investing.com UK
Alto Neuroscience Presents Phase 2a Data for ALTO-207 in Major Depressive Disorder at SOBP Annual Meeting - BioSpace
Alto Neuroscience reports positive phase 2a depression trial - Investing.com
Alto Neuroscience reports positive phase 2a depression trial By Investing.com - Investing.com Canada
Alto Neuroscience, Immunovant and other big stocks moving lower in Thursday's pre-market session - MSN
Top Alto Neuroscience (ANRO) Competitors 2026 - MarketBeat
Alto Neuroscience (ANRO) price target increased by 15.20% to 36.72 - MSN
ANRO stock on investors’ radar after failed schizophrenia study results - MSN
Alto Neuroscience, Inc. (NYSE:ANRO) Given Average Recommendation of "Moderate Buy" by Analysts - MarketBeat
Analysts Offer Insights on Healthcare Companies: Alto Neuroscience, Inc. (ANRO), Arcutis Biotherapeutics (ARQT) and Valneva (VALN) - The Globe and Mail
ANRO (Alto Neuroscience Inc.) Q4 2025 EPS misses forecasts, stock edges down 1.36 percent following its latest quarterly earnings release.Expert Momentum Signals - Xã Thanh Hà
Alto Neuroscience (NYSE:ANRO) Earns "Buy" Rating from Chardan Capital - MarketBeat
Alto Neuroscience (NYSE:ANRO) Reaches New 1-Year HighStill a Buy? - MarketBeat
Alto Neuro (ANRO) Stock Volume Deceleration (Surges) 2026-04-22Short Term Trading - Xã Châu Thành
Chardan Capital Maintains Alto Neuroscience(ANRO.US) With Buy Rating, Maintains Target Price $30 - Moomoo
Alto Neuroscience launches phase 2b trial for depression drug By Investing.com - Investing.com India
Alto Neuroscience (NYSE:ANRO) Shares Down 7.2%Here's Why - MarketBeat
Alto Neuroscience Starts Phase 2b Trial of ALTO-207 in Treatment-Resistant Depression - marketscreener.com
Alto Settles on Trials for Depression Drug - Baystreet.ca
Alto Neuroscience Initiates Phase 2b Trial of ALTO-207 in Treatment-Resistant Depression - BioSpace
Alto Neuroscience launches phase 2b trial for depression drug - Investing.com
[EFFECT] Alto Neuroscience, Inc. SEC Filing - Stock Titan
Four Major Data Readouts by 2026: Why Alto Neuroscience (ANRO) is on the Radar - AlphaStreet
ANRO Stock Price, Quote & Chart | ALTO NEUROSCIENCE INC (NYSE:ANRO) - ChartMill
Analysts’ Top Healthcare Picks: Boston Scientific (BSX), Alto Neuroscience, Inc. (ANRO) - The Globe and Mail
Alto Neuroscience (NYSE:ANRO) Hits New 52-Week HighHere's What Happened - MarketBeat
Alto Neuroscience (NYSE:ANRO) Trading 8.8% HigherHere's What Happened - MarketBeat
Wall Street Recap: Is Alto Neuroscience Inc benefiting from interest rate changes2026 Earnings Surprises & Fast Gaining Stock Strategy Reports - baoquankhu1.vn
Alto NeuroscienceProposed resale of up to 6 million shares of common stock by selling stockholdersSEC filing - marketscreener.com
Alto Neuroscience (NYSE: ANRO) registers 6M resale shares from private placement - Stock Titan
Top 1% Alto Neuroscience plummets on its shocking schizophrenia miss - MSN
What Do Analysts Think About the Biopharma Set on Transforming Psychiatry - Streetwise Reports
California Biotech Co. Advances Depression Drug Breakthrough - Streetwise Reports
Can Alto Neuro (ANRO) Stock Double in 2026 | Price at $21.99, Up 3.00%Reward Analysis - Xã Thanh Hà
Q1 Earnings Estimate for ANRO Issued By HC Wainwright - MarketBeat
Analysts Conflicted on These Healthcare Names: Merck & Company (MRK) and Alto Neuroscience, Inc. (ANRO) - The Globe and Mail
H.C. Wainwright reiterates Alto Neuroscience stock rating at buy By Investing.com - Investing.com Canada
Will Alto Neuro (ANRO) Stock Go Higher | Price at $21.63, Down 0.23%Fast Rising Picks - Cổng thông tin điện tử tỉnh Tây Ninh
Analysts Offer Insights on Healthcare Companies: Boston Scientific (BSX) and Alto Neuroscience, Inc. (ANRO) - The Globe and Mail
Alto Neuroscience, Immunovant And Other Big Stocks Moving Lower In Thursday's Pre-Market Session - Sahm
Crude Oil Rises Sharply; Acuity Shares Fall After Q2 Results - Sahm
Why Globalstar Shares Are Trading Higher By Around 12%; Here Are 20 Stocks Moving Premarket - Sahm
Analysts Offer Insights on Healthcare Companies: Jasper Therapeutics (JSPR), Alto Neuroscience, Inc. (ANRO) and Viridian Therapeutics (VRDN) - The Globe and Mail
0.14%
0.48%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):